title: Laryngeal manifestations of gastroesophageal reflux disease in children.
abstract: Although the association between gastroesophageal reflux disease (GERD) and laryngeal disorders in adults is well established there is still a lack of information concerning the true extent of the laryngeal complications of GERD in children. The aim of this study was to determine the laryngeal status of children with diagnosed GERD. We sought to identify the initial appearance of their larynges and then to determine the clinical response to antireflux therapy. GERD was recognized in 90/100 children examined. Using 24-h pH monitoring we found that most of the patients experienced episodes of gastroesophageal reflux during the daytime when they were in an upright position. The hallmark of GERD affecting the larynx in our group was posterior laryngitis, which is characterized by erythema of the mucous membrane overlying the arytenoid cartilages and the posterior mucosal wall of the glottis. The findings regarding the effectiveness of therapy were that, in children with severe laryngeal alterations, voice quality improved significantly after 12 weeks of antireflux treatment (p < 0.001) and laryngeal status was significantly better after 6 weeks of treatment (p < 0.001). This study provides evidence that gastroesophageal reflux in children is the underlying cause of inflammatory and morphological lesions, and that antireflux treatment is effective in reducing or eliminating these lesions.
authors.affiliation: Department of Otolaryngology, Medical University of Wrocław, Poland. krecicki@orl.am.wroc.pl
authors.forename: M
authors.initials: M
authors.lastname: Zalesska-Krecicka
authors.forename: T
authors.initials: T
authors.lastname: Krecicki
authors.forename: B
authors.initials: B
authors.lastname: Iwanczak
authors.forename: A
authors.initials: A
authors.lastname: Blitek
authors.forename: M
authors.initials: M
authors.lastname: Horobiowska
mesh_terms: D002648:Child; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007818:Laryngeal Diseases / Q000209:etiology*; D007827:Laryngitis / Q000209:etiology; D008297:Male; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D009853:Omeprazole